Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 1:32 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–68 of 68 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: The First Twenty Clear all

Conditions: Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML)
Interventions: PF-04449913; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Parents
Interventions: HPV Vaccine Education, Text Messaging Reminder; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years to 84 Years
Enrollment: 672 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2027
U.S. locations: 4
States / cities: Chicago, Illinois • Las Vegas, Nevada • New York, New York + 1 more

Conditions: Atypical Teratoid/Rhabdoid Tumor, Embryonal Tumor With Multilayered Rosettes, Ewing Sarcoma, Diffuse Intrinsic Pontine Glioma, Osteosarcoma, Neuroblastoma, DIPG Brain Tumor
Interventions: Eflornithine (DFMO), AMXT 1501 Dicaprate; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: Up to 26 Years
Enrollment: 265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 14
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Hartford, Connecticut + 11 more

Conditions: Myofascial Pain, Myofascial Trigger Point Pain
Interventions: 1% plain lidocaine and 0.25% plain bupivacaine; Combination Product
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Diabetic Macular Edema
Interventions: CU06-1004, Single dose, CU06-1004, Multiple doses, Placebo; Drug
Lead sponsor: Curacle Co., Ltd.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Gestational Diabetes Mellitus, Gestational Diabetes Mellitus in Pregnancy, Insulin Resistance
Interventions: Acute exercises sessions with different exercise types and intensities; Behavioral
Lead sponsor: University of Central Arkansas; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Conway, Arkansas

Conditions: Tumor, Solid
Interventions: BDB018, Pembrolizumab; Drug
Lead sponsor: Eikon Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: Sarasota, Florida • Grand Rapids, Michigan • San Antonio, Texas

Conditions: Urologic Surgical Procedure
Interventions: Ice pack; Other
Lead sponsor: Viraj Master; Other
Eligibility: 18 Years to 89 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Stage I Colon Cancer, Stage II Colon Cancer, Stage III Colon Cancer, Stage I Rectal Cancer, Stage II Rectal Cancer, Stage III Rectal Cancer
Interventions: questionnaire administration, laboratory biomarker analysis, Standard Dietary Intervention, Intensified Dietary Intervention, Low glycemic load, Medium Glycemic Load; Other · Behavioral
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: Cardiovascular Diseases, Type 2 Diabetes Mellitus in Obese, Hyperlipidemias
Interventions: CHAI dyad study; Behavioral
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 20 Years to 70 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Lymphoma, Lymphoma, B-Cell, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases
Interventions: iC9-CAR19 T cells, Bendamustine, Fludarabine, AP1903, Cyclophosphamide; Biological · Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2040
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Traumatic Brain Injury
Interventions: OSC-; Behavioral
Lead sponsor: Brigham Young University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Provo, Utah

Conditions: Non-Small Cell Lung Cancer
Interventions: Cyclical Hypofractionated Palliative Radiation (Quad Shot), EORTC QLQ-C30 questionnaire; Radiation · Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Speech Sound Disorder
Interventions: Visual-Acoustic Biofeedback Treatment, No Treatment; Behavioral · Other
Lead sponsor: Montclair State University; Other
Eligibility: 9 Years to 15 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Upper Montclair, New Jersey

Conditions: Physical Fitness
Interventions: The First Twenty, Comparison; Behavioral
Lead sponsor: Kansas State University; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Manhattan, Kansas

Conditions: Healthy, Dietary Supplement
Interventions: Ozone, Fish Oil, Olive Oil; Drug · Dietary Supplement
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 35 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Dry Eye, Neuropathic Pain
Interventions: Hyperosmolar Response, Proparacaine Challenge Test, Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) Optional; only for Contact Lens Wearers, Ocular Pain Assessment Survey (OPAS), Visual Analogue Questionnaire; Other
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 16
States / cities: Azusa, California • Pomona, California • San Francisco, California + 10 more

Conditions: Musculoskeletal Pain, Musculoskeletal Injury
Interventions: Execise Group, Control Group; Other
Lead sponsor: Loyola University; Other
Eligibility: Not listed
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: IgG4 Related Disease, IgG4-RD
Interventions: elotuzumab, placebo for elotuzumab, methylprednisolone, diphenhydramine, acetaminophen, famotidine, prednisone; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: Atlanta, Georgia • Boston, Massachusetts • Rochester, Minnesota

Conditions: Obesity
Interventions: The First Twenty (TF20), Life Simple 7 (LS7); Behavioral
Lead sponsor: National Development and Research Institutes, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 198 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: Leawood, Kansas • New York, New York

Search by objective public record fields.

Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS)

Edtech-HPV: A Community Approach Using Education and Technology to Increase HPV Vaccination

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

Investigating the Minimum Number of Needling Required to Optimize Trigger Point Injections Outcome

First-In-Human Study of CU06-1004 Following Single and Multiple Ascending Doses in Healthy Volunteers

Prenatal Exercise and Glucose Regulation

Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Minimizing Post-surgical Pain and Narcotic Administration Through Cryotherapy

Low Glycemic Load Diet in Patients With Stage I-III Colon Cancer

Implementation of a Peer Leader-facilitated Dyadic Intervention

Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma

Heart Rate Variability Biofeedback Following Traumatic Brain Injury

Radiation Therapy to Relieve Symptoms in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Visual Acoustic Biofeedback for RSE Via Telepractice

The First 20 Fire Academy Recruits Exercise Training Program

Efficacy of Fish Oil or Olive Oil Supplementation on the Health Effects of Ozone Exposure in Healthy Young Subjects

Neurosensory Abnormalities in SymptomAtic Ocular Surface Patients (NASA)

Surgeon Core-strengthening Program as a Modifier for Exertion Associated With Vaginal Surgery

Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)

The First Twenty (TF20) for Volunteer Firefighters in a Clinic Based Setting